Traders Buy Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Traders purchased 5,244 call options on the company. This is an increase of 124% compared to the average daily volume of 2,345 call options.

Wall Street Analyst Weigh In

ROIV has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a research note on Tuesday, June 18th. HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Monday, August 19th. Finally, Piper Sandler boosted their price target on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, July 10th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.10.

Roivant Sciences Stock Down 3.8 %

Roivant Sciences stock traded down $0.46 during trading hours on Tuesday, hitting $11.77. The company had a trading volume of 5,152,509 shares, compared to its average volume of 5,655,124. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. The firm has a market capitalization of $8.69 billion, a P/E ratio of 2.33 and a beta of 1.24. Roivant Sciences has a fifty-two week low of $8.24 and a fifty-two week high of $13.24. The firm's fifty day moving average is $11.12 and its 200-day moving average is $11.00.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.33. The company had revenue of $55.10 million during the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company's revenue for the quarter was up 155.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.38) earnings per share. On average, research analysts forecast that Roivant Sciences will post -1.14 earnings per share for the current year.

Institutional Trading of Roivant Sciences

Several large investors have recently modified their holdings of the company. nVerses Capital LLC bought a new stake in Roivant Sciences in the 2nd quarter valued at $34,000. Point72 Hong Kong Ltd acquired a new stake in shares of Roivant Sciences during the 2nd quarter worth about $36,000. Quarry LP acquired a new stake in shares of Roivant Sciences during the 2nd quarter worth about $53,000. Acadian Asset Management LLC acquired a new stake in shares of Roivant Sciences during the 1st quarter worth about $72,000. Finally, Fifth Third Wealth Advisors LLC acquired a new stake in shares of Roivant Sciences during the 2nd quarter worth about $101,000. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.